BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the...
Day: June 27, 2024
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for...
Tilray Brands Brews Up Summer Fun for the Fourth of July
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and...
KALA BIO Announces $12,500,000 Private Placement
ARLINGTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research,...
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
Boston (June 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company...
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-controlled trial conducted...
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
– Adds to comprehensive patent portfolio underlying novel ThermoStem® technology platform – – Expanding intellectual property estate expected to help...
Venus Concept Celebrates Successful Completion of its NEXThetics Events Across North America
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical...
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos’ Flagship CARE Oral...
Cronos Brand Spinach® Celebrates Summer with New Launches
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc.’s (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) Spinach® brand...
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF),...
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set...
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with...
OraSure Technologies Supports National HIV Testing Day
BETHLEHEM, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic...
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide...
Tilray Brands Announces Runner’s High Brewing Company – Its New Brand of Premium Non-Alcoholic Brews
Runner’s High Brewing Taps into the Social Running CommunityNEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray...
Expanded Access to XHANCE with Addition to National Commercial Formularies
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose...
Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery
DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced...
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using...
Oculis and EURETINA Announces the Ramin Tadayoni Award
ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a...